Home Magazines Editors-in-Chief FAQs Contact Us

Perspective of the β-blockers for the patients with diabetes and heart failure 


Abstract

Patients with diabetes and heart failure have been increasing due to Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study.β-blockers showed significantly suppressed cardiovascular events in the strict glycemic control group. Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)seem to be beneficial for diabetes and heart failure. Clinical efficacy of β-blockers would be suggested from three studies including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME)trial, Canagliflozin cardioVascular Assessment Study (CANVAS)and Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Further discussion will be expected with research in detail.

Keywords

Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study, The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, sodium–glucose cotransporter 2 (SGLT2) inhibitors

Testimonials